ESMO 2017: A pool of predictive biomarkers for response to immunotherapy could soon be available to select responsive patients

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Where we are

  • The use of immunotherapy in cancer is growing rapidly, with many new indications.
  • Patients response can vary widely even in the presence of similar clinical and genomic biomarkers.
  • In the absence of useful predictive tools for response, the clinical use of immunotherapy can b...